



Management of ST Segment Elevation Myocardial Infarction

- The recommended dose of Fondaparinux Sodium Injection is 2.5 mg once daily. The first dose of Fondaparinux Sodium Injection is administered intravenously, and subsequent doses are administered by subcutaneous injection.
- Treatment should be initiated as soon as possible following diagnosis and continued for up to 8 days or until hospital discharge.
- Fondaparinux Sodium Injection should not be used if primary Percutaneous Coronary Intervention (PCI) is the planned reperfusion therapy.
- Fondaparinux Sodium Injection is indicated for use in patients who are managed with thrombolytics or who initially are to receive no form of reperfusion therapy.
- If a patient is to undergo subsequent PCI while being treated with Fondaparinux Sodium Injection, an effective anti-thrombin regimen such as unfractionated heparin (UFH) should be administered as an adjunct to PCI as per standard practice
- The timing of the next dose of subcutaneous Fondaparinux after sheath removal should be based on clinical judgment. In the STEMI clinical trials treatment with Fondaparinux was restarted no earlier than 3 hours after sheath removal.
- In patients who are to undergo Coronary Artery Bypass Graft (CABG) surgery, fondaparinux where possible, should not be given during the 24 hours before surgery and may be restarted 48 hours post-operatively.

Reference: <https://www.drreddys.com/media/815576/fondaparinux-eng-pm.pdf>